We have developed a novel neuromodulation platform designed to measure a patient’s unique biomarkers for the treatment of chronic neurological conditions.
The Evoke® System Powered by SmartLoopTM Technology Redefines Spinal Cord Stimulation
Know the Dose
The Evoke System directly measures and records the characteristics of the neural activation. Using ECAPs, our system can quantify the level of stimulation to a desired target set by the clinician.
Control The Dose
Continuously compares the level of neural activation with the target level set by the clinician during programming and automatically adjusts the stimulation current of the next pulse to ensure a consistent level of neural activation.
You are not alone, ~67 Million Adults in the United States are living with chronic pain1
Learn more about people like you who discovered pain relief with the Evoke SmartSCSTM System
Todd’s Story
I started coaching again, I started being able to go outside and play with my kids, actually sitting on a couch, sitting in a chair, so all the normal things things that everyone else gets to do that I have to think about through my day
Todd G.
Evoke System Patient
Clinical Superiority
Proven in the EVOKE Study2
Born from more than a decade of advanced research, development, and clinical experience
Saluda® is built on more than 10 years of advanced research development and clinical experience. To our knowledge, Saluda is the first to directly measure the spinal cord’s physiologic response to stimulation using Evoked Compound Action Potentials (ECAPs) to pioneer smart neuromodulation therapy.3
The EVOKE Study 36-Month Data Publication
FDA Approval for Evoke System MRI Labeling
Publication of Economic Evidence Demonstrating Cost Dominance of Evoke Closed-Loop SCS over Open-Loop SCS
$150M Equity Financing Led by Wellington Management, Fidelity Management & Research Company and TPG
FDA approval (US)
- $125 M equity financing
- EVOKE RCT 24-month data published in JAMA Neurology
- US Centers for Medicare and Medicaid (CMS) Grants Transitional Pass-Through (TPT) Payment for Saluda’s Evoke System
- Initiation of US Commercialization of the Evoke System
- FDA Approval for Clarity™, 3rd Generation Programming Application for the Evoke System
TGA approval (AUS)
CE Mark approval (EU)
EVOKE RCT 12-month data published in The Lancet Neurology
First human implant (AUS)
First ECAP measured in a human (AUS)
First ECAP measured in a sheep (AUS)
Our Mission Is To Revolutionize Neuromodulation
People said it couldn’t be done and we just did it.
Peter Single
Chief Technology Officer
One of our core values at Saluda is that you can’t improve what you can’t measure. And we’ve taken that to heart. Our ability to measure in this space means that we can now go and look and improve upon the signals that we measure, improve upon the measurement capability, and then think about the therapies that can be improved by making that measurement.
Dean Karantonis
Sr. Vice President, Therapy Development